GlobeNewswire

Saniona presenterar prekliniska resultat för SAN903 på ASPETs årsmöte för experimentell biologi 2021

Dela

PRESSMEDDELANDE

14 april 2021

Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att bolagets vetenskapliga team kommer att presentera prekliniska resultat för SAN903 i en modell av idiopatisk lungfibros vid American Society of Pharmacology and Experimental Therapeutics (ASPET) årsmöte för experimentell biologi (EB) 2021, som kommer att hållas digitalt 27–30 april 2021.

SAN903 är en ny first-in-class-hämmare av den kalciumaktiverade kaliumjonkanalen KCa3.1. Jonkanalen återfinns i immunceller och fibroblaster där den reglerar spridningen, migrationen och frisättandet av cytokiner och kollagen. Tidigare studier har indikerat att hämning av KCa3.1 kan minska inflammation och fibros i samband med olika sjukdomar. Saniona utvärderar för närvarande SAN903 i prekliniska modeller av ett flertal sällsynta inflammatoriska och fibrotiska sjukdomar och räknar med att inleda kliniska studier under första halvåret 2022.

Vid ASPET-konferensen kommer Saniona att presentera en poster med rubriken “Comparison of KCa3.1 Inhibitor, SAN903, with Nintedanib and Pirfenidone in an Idiopathic Pulmonary Fibrosis Model.” Ett sammanfattande abstrakt (L5029) kommer att finnas tillgänglig på mötets webbplats och postern kommer att finnas tillgänglig för registrerade deltagare mellan 13 april och 31 maj 2021. Saniona avser också att delge sina prekliniska data om SAN903 i andra vetenskapliga forum och investerarsammanhang framgent.

“SAN903 upptäcktes i Sanionas laboratorier och utgör ett lysande exempel på den potential som vår proprietära plattform för läkemedelsupptäckt inom jonkanaler kan erbjuda när det kommer till nya behandlingar för sällsynta sjukdomar,” säger Jørgen Drejer, Sanionas Chief Scientific Officer. “Vi har tidigare i ett antal prekliniska modeller kunnat visa att SAN903 har förmåga att selektivt rikta in sig mot och fullständigt hämma KCa3.1, och de nya resultaten vi presenterar i samband med ASPET gör oss än mer övertygade om den potential molekylen har för behandling av sällsynta inflammatoriska och fibrotiska sjukdomar.”

För mer information, vänligen kontakta
Trista Morrison, Chief Communications Officer, Saniona. Kontor: + 1 (781) 810-9227. E-post: trista.morrison@saniona.com

Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 14 april 2021 kl. 14:00 CEST.

Om Saniona
Saniona är ett biofarmaceutiskt företag som fokuserar på att upptäcka, utveckla och leverera innovativa behandlingar för patienter med sällsynta sjukdomar världen över. För bolagets huvudkandidat, Tesomet, genomförs kliniska studier i mellanfas avseende de sällsynta sjukdomarna hypotalamisk fetma och Prader-Willis syndrom, allvarliga sällsynta sjukdomar som kännetecknas av okontrollerbar hunger och svårhanterlig viktuppgång. Sanionas robusta plattform för läkemedelsupptäckt har genererat ett bibliotek av mer än 20 000 proprietära jonkanalsmodulatorer - en i huvudsak outnyttjad läkemedelsklass som är vetenskapligt validerad. Huvudkandidaten SAN711 ska inleda fas 1-studier på sällsynta neuropatiska sjukdomar, och SAN 903 mot sällsynta inflammatoriska och fibrotiska sjukdomar avanceras i prekliniska studier. Under ledning av ett erfaret vetenskapligt och operativt team har Saniona en etablerad forskningsorganisation i Köpenhamn, och håller på att bygga upp företagets huvudkontor i Boston-området i Massachusetts, USA. Företagets aktie är listad på Nasdaq Stockholm Small Cap (OMX: SANION). Läs mer på www.saniona.com.

Bilaga

För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.
För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.

Om

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

IMCD N.V. publishes convocation for its upcoming Annual General Meeting11.5.2021 07:00:00 CEST | Press release

ROTTERDAM, The Netherlands (11 May 2021) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today published the convocation and agenda for its Annual General Meeting of shareholders (“AGM”), which will be held on Tuesday 22 June 2021 at 10:30 CET in Rotterdam, The Netherlands. The convocation, agenda, and further documentation for the AGM are available in the Investors’ section of IMCD’s website. In view of the continuing COVID-19 pandemic, precautionary measures apply to limit exposure for IMCD’s employees, shareholders, and other stakeholders. IMCD encourages shareholders to exercise their online proxy voting rights in advance of the meeting, instead of attending the meeting in person. There will be no social gathering surrounding the AGM and depending on the circumstances at the time, the number of board members participating may be limited. Shareholders are advised to regularly check the Investors’ section of IMCD’s website for any upd

Hexagon Purus ASA: Results for the first quarter 202111.5.2021 07:00:00 CEST | Press release

In the first quarter of 2021, Hexagon Purus Group generated NOK 57 (48) million in revenue and recorded operating profit before depreciation (EBITDA) of NOK -62 (-43) million. Revenue growth was driven by increased activity in hydrogen distribution applications as well as aerospace with slightly lower revenue contribution from heavy duty vehicle applications due to the completion of a battery electric (BEV) truck demonstration program in Q1 2020. Continued investments in personnel and infrastructure to support and accelerate Hexagon Purus’ future growth drive negative profitability. Key developments Signed joint venture agreements with CIMC Enric in March 2021 to enter China which is expected to be the world’s largest zero emission hydrogen vehicle and distribution marketSigned a multi-year agreement (as part of a broader agreement together with Hexagon Agility encompassing CNG solutions) to supply hydrogen distribution modules to Certarus. Under the agreement, Hexagon Purus received a

Hexagon Purus ASA: Results for the first quarter 202111.5.2021 07:00:00 CEST | Press release

In the first quarter of 2021, Hexagon Purus Group generated NOK 57 (48) million in revenue and recorded operating profit before depreciation (EBITDA) of NOK -62 (-43) million. Revenue growth was driven by increased activity in hydrogen distribution applications as well as aerospace with slightly lower revenue contribution from heavy duty vehicle applications due to the completion of a battery electric (BEV) truck demonstration program in Q1 2020. Continued investments in personnel and infrastructure to support and accelerate Hexagon Purus’ future growth drive negative profitability. Key developments Signed joint venture agreements with CIMC Enric in March 2021 to enter China which is expected to be the world’s largest zero emission hydrogen vehicle and distribution marketSigned a multi-year agreement (as part of a broader agreement together with Hexagon Agility encompassing CNG solutions) to supply hydrogen distribution modules to Certarus. Under the agreement, Hexagon Purus received a

KBC Group: First-quarter result of 557 million euros11.5.2021 07:00:00 CEST | Press release

Press Release Outside trading hours - Regulated information* Brussels, 11 May 2021 (07.00 a.m. CEST) KBC Group: First-quarter result of 557 million euros Light is starting to appear at the end of the tunnel thanks to the large-scale vaccination rollout that started in the first quarter of 2021. However, the coronavirus pandemic is still far from over and continues to cause human suffering and unprecedented economic upheaval all over the world. From the start of the crisis more than a year ago, we have taken responsibility in safeguarding the health of our staff and customers, while ensuring that services continue to be provided. We have also worked closely with government agencies to support all customers impacted by coronavirus, implementing various measures such as loan deferrals. We have, for example, granted payment holidays for 13.1 billion euros’ worth of loans under coronavirus-related moratoria (according to the EBA definition). For 91% of that figure, the moratoria have now ex

Arcadis awarded contract to help achieve sustainable mobility in Singapore11.5.2021 07:00:00 CEST | Press release

Amsterdam, May 11, 2021 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, today announced it has been awarded a SG$26 million (~€16 million) contract by the Land Transport Authority (LTA) in Singapore to provide project management support to supervise the construction of the North-South Corridor (NSC) project. Singapore’s North-South Corridor (NSC) was originally planned as an expressway but has since been reconceptualized to also accommodate Singapore’s longest Transit Priority Corridor (TPC) to help achieve the greener Walk-Cycle-Ride future that is central to the city state’s Land Transport Master Plan 2040 vision. With the goal of supporting active mobility usage to get more people walking and cycling, the corridor will feature dedicated and continuous bus lanes, key cycling routes, and pedestrian paths that are important commuter roads. This project will enhance Singapore’s infrastructure for urban mobility. A key part

Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer11.5.2021 07:00:00 CEST | Press release

Data from the first positive phase III study of a cancer immunotherapy in early, resected lung cancerStudies in personalised healthcare exploring tumour agnostic treatments that demonstrate the impact of coupling biomarker testing with targeted therapies to develop individualised treatment plansNew data, and drug combination strategies for the treatment of lymphoma from the largest haematology portfolio in industry Basel, 11 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held 4-8 June, 2021. A total of 132 abstracts that include a Roche medicine will be presented at this year's meeting. These data advance oncology by showing the importance of making patient-centric treatment decisions and providing tailored medical care based on specific cancer types. “We will be presenting data from across our diverse onc

REC Silicon - First quarter 2021 results11.5.2021 06:55:00 CEST | Press release

Oslo, Norway – May 11, 2021: REC Silicon ASA (REC Silicon) reported first quarter 2021 revenues of USD 28.1 million versus USD 36.0 million in the fourth quarter of 2020 and EBITDA of USD 4.0 million versus USD 1.9 million in the prior quarter. REC Silicon reported a cash balance of USD 131.5 million on March 31, 2021 compared to USD 134.9 million on December 31, 2020. The Company reported EBITDA contributed by the semiconductor materials segment of USD 10.8 million for the first quarter compared to USD 8.0 million in the first quarter 2020 and USD 11.7 million for the fourth quarter of 2020. The decrease in EBITDA compared to the prior quarter was primarily the result of lower silicon gas sales volumes of 781 MT for the first quarter compared to 881 MT for the prior quarter. “The demand for semiconductor polysilicon and silicon gas has strengthened over the last quarters and we expect this trend to continue. Limited shipping availability over the Pacific has created some problems in f